Objectives: To determine the significance of molecular diagnosis of lymph node metastasis using quantitative reverse transcription polymerase chain reaction in patients with upper urinary tract urothelial cancer. Methods: A total of 51 patients with upper urinary tract urothelial cancer who underwent extended lymphadenectomy were included in the present study. Retrieved lymph nodes from each patient were divided into two parts. One part was assessed by quantitative reverse transcription polymerase chain reaction assay for molecular staging, whereas the other one was assessed by routine histopathological examination. Four kinds of molecules (FXYD3, KRT19, KRT20 and UPK2) were selected as markers to detect urothelial cancer cells. Results: The average number of retrieved lymph nodes was 18.3. As UPK2 showed the best discrimination ability among four markers, the patients were classified in three categories according to UPK2 expression: N(+)PCR(+) for patients who had lymph node metastasis by routine pathological diagnosis as well as quantitative reverse transcription polymerase chain reaction (n = 4); N(À)PCR(+) for patients who had lymph node metastasis by polymerase chain reaction but not by routine pathological diagnosis (n = 7); and N(À)PCR(À) for patients who showed no lymph node metastasis not only by routine pathological diagnosis but also by polymerase chain reaction (n = 40). The prognosis of the N(À)PCR(+) group was better than that of the N(+)PCR(+) group, and similar to that of the N(À)PCR(À) group. Conclusions: Quantitative reverse transcription polymerase chain reaction could detect micrometastasis in patients with upper urinary tract urothelial cancer. However, the prognosis of patients with micrometastasis is better than patients with pathologically metastasized lymph nodes, and similar to patients without micrometastasis.
Introduction
Recent reports have shown support for the staging and therapeutic benefits of extended lymphadenectomy, including the common iliac and presacral nodes, in patients with bladder cancer. 1 However, in patients with UTUC, the significance of lymphadenectomy has yet to be clarified in a diagnostic aspect, as well as in therapeutic benefits. In order to examine its significance, we carried out a multicenter prospective clinical trial of extended lymphadenectomy in patients with UTUC (UMIN ID: 000002519).
Lymph node staging is usually limited to routine pathological evaluation using hematoxylin-eosin stained sections of regional lymph nodes. Molecular techniques, such as qRT-PCR, can be applied to determine the presence of micrometastasis in lymph nodes that has been overlooked by routine histological examination. Three studies using the qRT-PCR technique were reported in patients with muscle-invasive bladder cancer who underwent total cystectomy with lymphadenectomy. [2] [3] [4] Although UTUC has many similar characteristics to bladder cancer, no study on molecular lymph node staging of UTUC has been published yet.
In the present study, we applied the qRT-PCR technique to retrieve lymph nodes by extended lymphadenectomy in patients with UTUC to determine the significance of molecular diagnosis for lymph node metastasis. We examined the clinical features of UTUC patients who showed only micrometastasis in lymph nodes determined by qRT-PCR.
Methods Extended lymphadenectomy
From December 2009 to June 2013, 51 patients with UTUC underwent nephroureterectomy with extended lymphadenectomy at Wakayama Medical University, Wakayama, and Tokyo Women's Medical University, Tokyo, Japan. This prospective study was approved by the Institutional Review Board of Wakayama Medical University (no. 700) and registered at the University Hospital Medical Information Network (UMIN 000002519). The anatomical extent of lymph node dissection was as previously described. 5 Briefly, the dissection area of the right renal pelvic cancer was the renal hilar, paracaval, retrocaval and interaortocaval lymph nodes. In the left renal pelvic cancer cases, the hilar and para-aortic lymph nodes were dissected. In patients with right upper two-thirds ureteral cancer, renal hilar, paracaval, retrocaval and inter aortocaval lymph nodes were dissected. In patients with left upper two-thirds ureteral cancer, renal hilar and para-aortic lymph nodes were dissected. For patients with lower onethird ureteral cancer in both sides, common iliac, external iliac, internal iliac and obturator lymph nodes were dissected (Fig. 1) . Lymph nodes were resected as whole tissue in the dissection area. Excised tissue was placed on a map illustrating the dissection area. Then lymph nodes were isolated manually, as lymph nodes were felt as solid tissue in adipose tissue. Isolated lymph nodes were placed on the same map, showing the original position. Then we took photographs and each lymph node was assigned a number for further analysis.
qRT-PCR
Retrieved lymph nodes from each patient were divided in two parts. One was immersed in RNA later (Qiagen, Venlo, the Netherlands) and stored at À80°C until RNA extraction, and the other was provided for routine pathological examination. Total RNA was extracted using RNAeasy Plus Mini (Qiagen). Extracted RNA was reverse transcribed with a random primer mix in a 40 ll reaction mix using SuperScript VILO cDNA Synthesis kit (Life Technologies, Carlsbad, CA, USA). Four kinds of molecules (FXYD3, KRT19, KRT20 and UPK2) were selected as markers to detect urothelial cancer cells. 3, 4 Gene expression quantification of the selected genes was carried out using TaqMan Gene Expression Assay (Life Technologies) and an Applied Biosystems StepOne (Life Technologies) according to the manufacturer's recommendations. The assay ID of each primer was as follows: FXYD3: Hs00254211_m1, KRT19: Hs00761767_s1, KRT20: Hs00300643_m1, UPK2: Hs03988971_g1 and beta-actin: Hs03023943_g1. Synthesized cDNA and each primer were reacted with TaqMan gene expression master mix (Cat#: 4369016). All samples were analyzed in duplicate and the Ct mean was obtained for further calculation. The beta-actin gene was used as the endogenous control. As a calibrator sample, histologically proven metastasized lymph nodes in patients with UTUC were used. The relative expression level of the marker genes for each sample was calculated by the ⊿Ct method using the average Ct of the endogenous control (beta-actin) and the average Ct of the target gene. 
Statistical analysis
The Kruskal-Wallis test was applied to compare the association with conventional prognostic indicators according to lymph node metastasis detected by histological examination and qRT-PCR assay.
We used the lymph node metastasis rate as the primary outcome. We evaluated the biomarkers affecting the presence and absence of lymph node metastasis using logistic regression. The estimated model that had the minimum BIC was selected, and the factor in the selected model was interpreted as the most influential biomarker. Biomarker values were reported as the mean AE standard deviation. Data analyses were carried out by using the statistical software JMP Pro 12 (SAS Institute, Cary, NC, USA). All P-values were twotailed, and P < 0.05 was defined as statistically significant.
The progression-free survival rates were calculated using the Kaplan-Meier method, and differences in survival among groups were compared using the log-rank test. A two-tailed P < 0.05 was taken to show statistical significance for all analyses, and all confidence intervals were 95%. The hazard ratio between each group was calculated by Cox proportional hazards regression analysis.
Results

Patients' characteristics
Baseline characteristics for all 51 patients are shown in Table 1 . The median age was 68 years (range 51-86 years), and 41 patients (80.4%) were men. A total of 30 patients (58.8%) had renal pelvic cancer, nine (17.7%) had upper two-thirds ureteral cancer, and 12 (23.5%) had lower onethird ureteral cancer. Pathologically proven lymph node metastases were observed in five lymph nodes of four (7.8%) patients. LVI was observed in 17 (33.3%) patients, while 12 (23.5%) patients had disease progression.
Number of removed lymph nodes according to the primary site Table 2 shows the number of retrieved lymph nodes according to primary sites. The average number of removed lymph nodes was 19.0 and 19.2, respectively, in the right and left renal pelvic cancer, 17.0 and 16.6, respectively, in the right and left upper two-thirds ureteral cancer, and 16.3 and 18.5, respectively, in the right and left lower one-third ureteral cancer. There was no significant difference in the total node count between the tumor locations. Total n = 51. of the marker molecule is the same as b-actin. If ⊿Ct has a minus value, expression of the marker molecule is stronger than b-actin. When no amplification was found, these lymph nodes were considered as "not amplified." The expression of FXYD3 and KRT19 was rather strong, as amplifications of these molecules were observed in most cases. Contrary to that, the expression of UPK2 and KRT20 were weak, as no amplification was found in half and quarter lymph nodes. We evaluated the biomarkers affecting the interest in pN0 and pN1/2 lymph nodes using logistic regression. BIC of four kinds of marker molecules are shown in Figure 3 . The estimated model that had the minimum BIC was selected, and the factor(s) in the selected model was interpreted as the most influential biomarker(s). Biomarker values were reported as the mean AE standard deviation. We compared the BIC of four kinds of marker molecules to select the best marker to distinguish pN1/2 from pN0 lymph nodes. Furthermore, we calculated the BIC of combination using two, three and four covariates. Interestingly, the lowest BIC was UPK2 as a single covariate. All combinations of multiple covariates were worse than UPK2 as a single covariate. Thus, we selected UPK2 as a marker molecule to detect metastasis of urothelial cancer to lymph nodes. We determined the cut-off value at 6.0.
RT-PCR
According to the cut-off at 6.0 of UPK2, 21 lymph nodes in 11 patients were determined to have micrometastasis by PCR. Among them, five lymph nodes in four patients were diagnosed as lymph node metastasis by routine pathological diagnosis. From these results, we classified the patients in three categories. First, the N(+)PCR(+) category was for four patients who had lymph node metastasis by routine pathological diagnosis. PCR amplification of UPK2 was observed in all these lymph nodes. Second, the N(À)PCR(+) category was for seven patients who had lymph node metastasis by PCR, but not by routine pathological diagnosis. The third category, N(À)PCR(À), was for the remaining 40 patients who showed no lymph node metastasis, not only by routine pathological diagnosis, but also by PCR. Figure 4 shows lymph node mapping of N(+)PCR(+) patients (n = 4). The purple circles represent N+ and PCR+ lymph nodes, while the blue circles represent NÀ but PCR+ lymph nodes. The green star shapes represent the primary tumor site. In cases 10 and 18, only N(+)PCR(+) lymph nodes were observed. In contrast, four N(À)PCR(+) lymph nodes were found surrounding N(+)PCR(+) lymph nodes in two patients. Three of these four patients had renal pelvic cancer, and metastasized lymph nodes were observed around the inferior mesenteric artery and renal hilus. One patient with upper ureter cancer had metastasized lymph nodes also around the inferior mesenteric artery. Figure 5 shows lymph node mapping of N(À)PCR(+) patients (n = 7). Three patients (cases 26, 27 and 37) had renal pelvic cancer. N(À)PCR(+) lymph nodes were observed in the renal hilus area. In case 26, UPK2 amplification was found in two lymph nodes. One patient (case 1) had upper ureter cancer. In this case, N(À)PCR(+) lymph node was observed in the inferior mesenteric artery area. Two patients (cases 12 and 20) had lower ureter cancer where the N(À) PCR(+) lymph nodes were found in the common iliac area. Table 3 shows a comparison of the pathological findings according to lymph node metastasis detected by histological examination and qRT-PCR assay. No significant difference was found in terms of T stage. With regard to tumor grade, the N(À)PCR(+) group showed a similar tendency to the N (À)PCR(À) group, but not to the N(+)PCR(+) group, as a significant difference was found between N(+)PCR(+) and N 
(À)PCR(+), but not between N(À)PCR(+) and N(À)PCR(À).
The same result was observed for LVI. Figure 6 shows Kaplan-Meier curves comparing progression-free survival of patients according to the molecular (PCR) and pathological (N) detection of the disseminated disease. The median follow-up time was 46.4 months. Although a significant difference was not observed (P = 0.159, logrank test), the N(+)PCR(+) group showed the tendency of a worse prognosis. The N(À)PCR(+) group showed the same tendency as the N(À)PCR(À) group as opposed to the N(+) PCR(+) group. The hazard ratio of NÀPCRÀ versus NÀPCR+, N+PCR+ versus NÀPCR+, and N+PCR+ versus NÀPCRÀ was 1.13 (P = 0.86), 3.79 (P = 0.15) and 3.13 (P = 0.13), respectively. Three out of four N+PCR+ patients showed progression in lymph nodes within and/or beyond the dissected area. Two out of seven NÀPCR+ patients had recurrences in the lung with and without lymph node recurrence. A total of 11 out of 40 NÀPCRÀ patients relapsed in various sites (lung: 4, lymph node: 7, liver: 2, bone: 1, port site: 1, multiple sites were independently counted).
Discussion
A clear definition of regional lymph nodes of UTUC has yet to be clarified due to a wide range of primary tumors. In addition, the diagnostic and therapeutic significance of lymphadenectomy in patients with UTUC remains unclear. We examined the micrometastasis that could not be identified by routine pathological examination by using the qRT-PCR technique. The present results showed that the qRT-PCR technique could identify micrometastasis in lymph nodes, and the patients with micrometastasis presented similar characteristics to the patients without micrometastasis, but not to the patients with histologically proven metastasis. We collected 932 lymph nodes from 51 patients with UTUC. Compared with previous reports, a sufficient number of lymph nodes were resected in the present study. 6, 7 Pathological metastasis of lymph nodes was observed in five lymph nodes in four patients.
Normal LN N(-)PCR(+) LN
We applied the qRT-PCR technique to the 932 dissected lymph nodes. We chose four kinds of molecules specific to urothelial cancer cell. Kurahashi et al. used KRT19 and UPK2 as specific markers for detection of micrometastasis in 40 patients who underwent total cystectomy. 3 In contrast, Marin-Aguilera et al. searched for the best marker molecules to detect urothelial cancer cells from five candidates. They found that the combination of FXYD3 and KRT20 yielded a good discrimination ability. They also applied the combination of FXYD3 and KRT20 to retrieved RNA from formalinfixed paraffin-embedded lymph nodes of patients with muscle-invasive bladder cancer. 2 From these results, we decided to use these four molecules to detect micrometastasis. We confirmed that these four molecules were well expressed in primary tissue, as well as in pathologically proven lymph node metastasis in patients with UTUC.
First, we evaluated the biomarkers affecting the presence and absence of lymph node metastasis using logistic regression. The estimated model that had the minimum BIC was selected. Furthermore, we calculated the BIC of combination using two, three and four covariates. Interestingly, the lowest BIC was UPK2 as a single covariate. Therefore, we defined the cut-off value using UPK2 as a single covariate.
According to the cut-off value of UPK2, 21 lymph nodes in 11 patients were determined to have urothelial cancer cells by qRT-PCR (PCR+). Among them, five lymph nodes in four patients were proven to have metastasis also by routine histological examination, N(+)PCR(+): cases 10, 18, 19 and 38. Interestingly, an additional eight lymph nodes surrounding pathologically positive lymph nodes were proven to have metastasis only by qRT-PCR in two patients (cases 19 and 38; Fig. 4) . In seven patients who were judged as pN0 by routine histological examination, micrometastasis was found by qRT-PCR in eight lymph nodes, N(À)PCR(+): cases 1, 12, 20, 25, 26, 27 and 37. Although only one lymph node was found to be positive on qRT-PCR in most patients, two lymph nodes were found to be positive in one case (case 26; Fig. 5 ). In the remaining 40 patients, no metastasis was found by pathological examination or qRT-PCR, N(À)PCR(À).
Although there are no significant differences among the three groups with respect to T stage, there was a significant difference with respect to tumor grade and LVI among N(+) and N(À) groups. The profile of the N(À)PCR(+) group was similar to that of the N(À)PCR(À) group, but not to the N(+) PCR(+) group. With regard to the progression-free survival rate, the same tendency was found, although the difference did not reach statistical significance. One of the reasons why the difference did not reach statistical significance was the number of N+PCR+ patients was small (n = 4). According to numerous studies, 3-year recurrence-free survival of N+ patients is 25-35%. 8 When we calculated the hazard ratio using our historical control (13 N+ patients who underwent nephroureterectomy in Wakayama Medical University), the hazard ratio of N+PCR+ versus NÀPCR+ and N+PCR+ versus NÀPCRÀ was 6.28 (P = 0.0059) and 6.24 (P < 0.0001). Considering these factors, the present results were rather convincing.
These results did not align with our expectations, as we had initially expected the prognosis of patients with micrometastasis to be worse than that of patients without micrometastasis, and rather similar to patients with pathologically proven metastasis. However, the present results showed that the clinical profile of the N(À)PCR(+) group was similar to the N(À)PCR(À) group.
As previously mentioned, there are three reports on micrometastasis by qRT-PCR on urothelial bladder cancer patients. Kurahashi et al. used KRT19 and UPK2 as specific markers for detection of micrometastasis in 40 patients who underwent total cystectomy. 3 They identified 12 patients who had micrometastasis by qRT-PCR out of 34 patients who were diagnosed as pN0 by routine pathological examination. Pathological features and prognoses in the N(À)PCR(+) group were significantly worse than the N(À)PCR(À) group. In contrast, Marin-Aguilera et al. reported that FXYD3 and KRT20 could be excellent markers to detect micrometastasis. 4 They found that the cancer-specific survival of the N(+) patients was significantly worse than that of the N(À) group. However, no significant difference was found between the N(À)PCR(+) and N(À)PCR(À) groups. They also applied the combination of FXYD3 and KRT20 to retrieved RNA from formalin-fixed paraffin-embedded lymph nodes of patients with muscle invasive bladder cancer. 2 Although they found a tendency for the patients with micrometastasis to have a worse clinical outcome than those without micrometastasis, the difference did not reach statistical significance. Although the detecting method was different, there was another study regarding micrometastasis of lymph nodes in bladder cancer patients. Mastumoto et al. used an immunohistochemical technique to detect micrometastasis, and showed that there was no difference regarding clinical outcome between patients with micrometastasis and without micrometastasis. 9 In fact, it is controversial whether the patients with micrometastasis in lymph nodes show a worse clinical outcome than the patients without micrometastasis. One systematic review regarding gastric cancer concluded that eight studies found no association, whereas 18 studies found micrometastasis was associated with a poorer prognosis. However, just six studies presented a significantly different 5-year survival rate between patients with and without micrometastasis. 10 The present results showed that there was no difference regarding clinical outcome between the patients with micrometastasis and without micrometastasis. We assume two hypotheses. One hypothesis is that the presence of a few urothelial cancer cells detected by qRT-PCR does not necessarily develop to clinical metastasis. Cancer cells circulate in the body more frequently than we had expected. However, not all of them could develop clinical metastasis, as our immune cells are constantly eradicating circulating cancer cells. The second hypothesis is that extended lymphadenectomy could have a therapeutic benefit. This hypothesis seems to be attractive. However, it is considerably difficult to prove.
There were several limitations in the present study. First, because of the small number of patients, just five pathologically metastasized lymph nodes in four patients were identified. We require a higher number of patients to determine a more sophisticated method of detecting micrometastasis. Second, we only applied the qRT-PCR technique to detect micrometastasis. Following a study that used an immunohistochemical technique to detect micrometastasis in patients with UTUC, we also attempted to identify micrometastasis using an immunohistochemical method. 6 However, as the pathological evaluation is more challenging in immunohistochemistry, we decided to use the qRT-PCR technique for the present study. Third, the retrieved lymph nodes were divided in two groups in the present study. This could underestimate the entity of nodal burden, as not all nodes were sent to pathology. Although we do not know whether usual pathological examination could identify microscopic lymph node metastasis identified by PCR, they may have found metastasis if all the specimens were subjected to pathological examination.
In conclusion, qRT-PCR could detect micrometastasis in patients with UTUC who underwent nephroureterectomy with extended lymph node dissection. However, the prognosis of patients with micrometastasis is better than patients with pathologically metastasized lymph nodes, and is similar to that of patients without micrometastasis.
